At IRBM, our experience in the development of custom assays is leveraged into a robust, efficient and multi-parameter validation platform to confirm the biological and pathological role of your novel target. The data package generated by our team can then be transferred seamlessly forward for Hit Identification.


Our Offering:

  • In vitro and In vivo gene knock-out and over-expression studies;
  • Expression profiling in relevant proprietary or commercially available cell lines;
  • Development and deployment of bioassays to measure biological activity and characterize the pharmacology of the target;
  • Target deconvolution.